
Thursday, November 23, 2017 2:10:50 PM
The Center for Medicare and Medicaid Services (CMS) released the final 2018 Clinical Laboratory Fee Schedule (CLFS) today, re-affirming the preliminary rate for AlloMap of $3,240, an increase of 14% compared with the 2017 CMS CLFS rate of $2,840.75. The higher 2018 reimbursement rate for AlloMap was due in part to effective claims management, which increased the weighted median of commercial reimbursement. This data was shared with CMS as required by regulations associated with the Protecting Access to Medicare Act of 2014 (PAMA). The effective date of the increase is January 1, 2018.
“The implementation of PAMA by CMS provides a refreshing predictability to the reimbursement of diagnostic tests,” said Sasha King, Chief Commercial Officer at CareDx. “The updated rate highlights the value AlloMap brings to heart transplant patients.”
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Volume: | 899,634 |
Day Range: | 22.24 - 24.02 |
Bid: | 22.10 |
Ask: | 23.00 |
Last Trade Time: | 7:53:10 PM EST |
Total Trades: | 14,045 |
Recent CDNA News
- CareDxが研究結果を発表、AlloSeq cfDNAが臓器移植患者の拒絶反応検出に高い精度を示す • Business Wire • 02/21/2025 02:13:00 AM
- CareDx publie une étude confirmant la grande précision d’AlloSeq cfDNA dans la détection du rejet chez les patients transplantés • Business Wire • 02/20/2025 10:31:00 PM
- CareDx gibt Studie bekannt, die zeigt, dass AlloSeq cfDNA bei der Erkennung von Abstoßungsreaktionen bei Organtransplantationspatienten äußerst genau ist • Business Wire • 02/20/2025 09:03:00 PM
- CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients • Business Wire • 02/20/2025 12:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/14/2025 04:23:34 PM
- CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies • Business Wire • 02/13/2025 12:05:00 PM
- CareDx to Report Fourth Quarter and Full Year 2024 Financial Results • Business Wire • 02/11/2025 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2025 09:30:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2025 02:01:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2025 09:30:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/04/2025 09:18:48 PM
- CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results • Business Wire • 01/13/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2025 09:32:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2025 09:30:15 PM
- CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/18/2024 12:05:00 PM
- CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy • Business Wire • 12/11/2024 12:00:00 PM
- TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy • PR Newswire (US) • 12/11/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 09:32:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/04/2024 09:42:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2024 01:54:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2024 09:31:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/26/2024 09:25:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/25/2024 09:45:36 PM
ConnectM Announces Q1 2025 Preliminary Revenue Guidance of $11.3M, Representing a 100% Year-Over-Year Surge • CNTM • Feb 21, 2025 7:17 AM
Consumer Automotive Finance Inc. (CAFI) Completes Final Steps with FINRA, Expects Name and Ticker Change to Fifty 1 Labs, Inc. (FITY) Within 30 Days • CAFI • Feb 20, 2025 9:00 AM
UAV Corp Unveils AIG's Arrival and Cutting-Edge 3D Printing Technology, Paving the Way for Full-Scale T-Wing UAS Production and the Future of Aerospace and Defense Manufacturing • UMAV • Feb 20, 2025 8:30 AM
North Bay Resources Announces Production of 8.5 Ounces Per Ton Gold Concentrate, Bishop Gold Mill, California • NBRI • Feb 19, 2025 8:59 AM
YCRM ReachOut Technology Returns to Trading: CEO Rick Jordan Lays Out Blockchain CyberSecurity Strategy and Industry-First AI MSP Partnership In Shareholder Letter • YCRM • Feb 18, 2025 11:20 AM
VAYK Confirms No Dilution Following Recent Acquisition and 11 Million Insider Purchase • VAYK • Feb 18, 2025 9:30 AM